Ticker brief
LSTA
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
5
crowd 14d
+0.20
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-15 · now +0.10 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @proactive_x | C | -1.13 | 3 | +0.23 |
| @OzmosiHealth | C | · | 2 | +0.25 |
| @BiopharmIQ | B | · | 1 | +0.20 |
| @PrismMarketView | C | · | 1 | +0.25 |
| @PrismDM | A | -2.76 | 1 | +0.20 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @proactive_x | +0.10 | Lisata appointed biopharma finance veteran Jeffrey Farrow to its board. | · | tweet ↗ |
| 2026-10-08 | @PrismDM | +0.20 | Reports a new U.S. method-of-use patent for certepetide lasting to May 2041, while noting it is not approval. | · | tweet ↗ |
| 2026-10-08 | @PrismMarketView | +0.25 | Reports a new U.S. method-of-use patent extending claimed oncology-candidate exclusivity. | · | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | +0.20 | Biotech roundup reports acquisition, trial approval, study and financing events. | · | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.30 | Lisata received a new method-of-use patent for certepetide. | · | tweet ↗ |
| 2026-10-08 | @proactive_x | +0.30 | Lisata Therapeutics received a new US patent covering its pancreatic-cancer drug. | · | tweet ↗ |
| 2026-10-05 | @OzmosiHealth | +0.20 | Lisata subsidiary Marea announced the first patient dosed in a Phase 2 MAR002 trial. | · | tweet ↗ |
| 2026-10-05 | @proactive_x | +0.30 | Lisata subsidiary Marea treats the first patient in its MAR002 trial. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.